285 related articles for article (PubMed ID: 26368744)
1. Nine-year change in statistical design, profile, and success rates of Phase II oncology trials.
Ivanova A; Paul B; Marchenko O; Song G; Patel N; Moschos SJ
J Biopharm Stat; 2016; 26(1):141-9. PubMed ID: 26368744
[TBL] [Abstract][Full Text] [Related]
2. Optimal and minimax three-stage designs for phase II oncology clinical trials.
Chen K; Shan M
Contemp Clin Trials; 2008 Jan; 29(1):32-41. PubMed ID: 17544337
[TBL] [Abstract][Full Text] [Related]
3. Five-year change in statistical designs of phase II trials published in leading cancer journals.
Thezenas S; Duffour J; Culine S; Kramar A
Eur J Cancer; 2004 May; 40(8):1244-9. PubMed ID: 15110889
[TBL] [Abstract][Full Text] [Related]
4. How a new stratified adaptive phase II design could improve targeting population.
Tournoux-Facon C; De Rycke Y; Tubert-Bitter P
Stat Med; 2011 Jun; 30(13):1555-62. PubMed ID: 21432892
[TBL] [Abstract][Full Text] [Related]
5. Formal statistical testing and inference in randomized phase II trials in medical oncology.
Saad ED; Sasse EC; Borghesi G; Miranda VC; Fede AB; Saad LS; Oliveira V; Barros EA; Pascoin M; Del Giglio A; Riechelmann R
Am J Clin Oncol; 2013 Apr; 36(2):143-5. PubMed ID: 22307212
[TBL] [Abstract][Full Text] [Related]
6. Phase II cancer clinical trials for biomarker-guided treatments.
Jung SH
J Biopharm Stat; 2018; 28(2):256-263. PubMed ID: 28902567
[TBL] [Abstract][Full Text] [Related]
7. Mixed response and time-to-event endpoints for multistage single-arm phase II design.
Lai X; Zee BC
Trials; 2015 Jun; 16():250. PubMed ID: 26037094
[TBL] [Abstract][Full Text] [Related]
8. Optimal decision-making in oncology development programs based on probability of success for phase III utilizing phase II/III data on response and overall survival.
Götte H; Xiong J; Kirchner M; Demirtas H; Kieser M
Pharm Stat; 2020 Nov; 19(6):861-881. PubMed ID: 32662598
[TBL] [Abstract][Full Text] [Related]
9. A flexible multi-stage design for phase II oncology trials.
Tan MT; Xiong X
Pharm Stat; 2011; 10(4):369-73. PubMed ID: 22328328
[TBL] [Abstract][Full Text] [Related]
10. Improving the flexibility and efficiency of phase II designs for oncology trials.
Englert S; Kieser M
Biometrics; 2012 Sep; 68(3):886-92. PubMed ID: 22150825
[TBL] [Abstract][Full Text] [Related]
11. Does Cancer Literature Reflect Multidisciplinary Practice? A Systematic Review of Oncology Studies in the Medical Literature Over a 20-Year Period.
Holliday EB; Ahmed AA; Yoo SK; Jagsi R; Hoffman KE
Int J Radiat Oncol Biol Phys; 2015 Jul; 92(4):721-31. PubMed ID: 26104927
[TBL] [Abstract][Full Text] [Related]
12. Statistical issues for design and analysis of single-arm multi-stage phase II cancer clinical trials.
Jung SH
Contemp Clin Trials; 2015 May; 42():9-17. PubMed ID: 25749311
[TBL] [Abstract][Full Text] [Related]
13. Setting the bar in phase II trials: the use of historical data for determining "go/no go" decision for definitive phase III testing.
Vickers AJ; Ballen V; Scher HI
Clin Cancer Res; 2007 Feb; 13(3):972-6. PubMed ID: 17277252
[TBL] [Abstract][Full Text] [Related]
14. Performance of adaptive designs for single-armed phase II oncology trials.
Kieser M; Englert S
J Biopharm Stat; 2015; 25(3):602-15. PubMed ID: 24905363
[TBL] [Abstract][Full Text] [Related]
15. Phase II multi-step planning methods in oncology: comparison, recommendations and potential applications.
Medioni J; de Rycke Y; Tournoux Facon C; Mallet A; Asselain B
Contemp Clin Trials; 2007 May; 28(3):249-57. PubMed ID: 17113357
[TBL] [Abstract][Full Text] [Related]
16. Current issues in oncology drug development, with a focus on Phase II trials.
Sargent DJ; Taylor JM
J Biopharm Stat; 2009; 19(3):556-62. PubMed ID: 19384696
[TBL] [Abstract][Full Text] [Related]
17. Optimal adaptive two-stage designs for early phase II clinical trials.
Shan G; Wilding GE; Hutson AD; Gerstenberger S
Stat Med; 2016 Apr; 35(8):1257-66. PubMed ID: 26526165
[TBL] [Abstract][Full Text] [Related]
18. An optimal three-stage design for phase II clinical trials.
Ensign LG; Gehan EA; Kamen DS; Thall PF
Stat Med; 1994 Sep; 13(17):1727-36. PubMed ID: 7997706
[TBL] [Abstract][Full Text] [Related]
19. Multistage designs for phase II clinical trials: statistical issues in cancer research.
Kramar A; Potvin D; Hill C
Br J Cancer; 1996 Oct; 74(8):1317-20. PubMed ID: 8883425
[TBL] [Abstract][Full Text] [Related]
20. Methods for proper handling of overrunning and underrunning in phase II designs for oncology trials.
Englert S; Kieser M
Stat Med; 2015 Jun; 34(13):2128-37. PubMed ID: 25781860
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]